In a 29-year-old Black male with proximal muscle weakness, modest creatine kinase elevation, anti‑U1‑RNP antibody level of 4.7 U (positive) and a negative ENA panel, what is the most likely diagnosis—mixed connective tissue disease, systemic lupus erythematosus, or anti‑U1‑RNP‑associated inflammatory myopathy?

Most Likely Diagnosis: Anti-U1-RNP-Associated Inflammatory Myopathy

Based on your presentation—a 29-year-old Black male with proximal muscle weakness, modest CK elevation, isolated anti-U1-RNP positivity (4.7 U) and negative remainder of ENA panel—the most likely diagnosis is anti-U1-RNP-associated inflammatory myopathy rather than MCTD or SLE. This represents a distinct clinical entity that shares features with but does not fully meet criteria for either MCTD or lupus.

Diagnostic Reasoning

Why Anti-U1-RNP Myopathy is Most Likely

Your clinical picture aligns precisely with the phenotype described in the highest-quality study on this topic 1:

• Demographics match perfectly: Anti-U1-RNP myositis patients are younger (mean ~37 years) and disproportionately Black (60% in the cohort) 1
• Muscle weakness as presenting feature: While only 15% present initially with weakness, 80% eventually develop it—you're presenting with this cardinal feature 1
• Modest CK elevation: Anti-U1-RNP myopathy typically shows less dramatic CK elevations than immune-mediated necrotizing myopathy 1
• Isolated anti-U1-RNP positivity: The negative remainder of your ENA panel argues against SLE, which typically shows multiple autoantibodies

Why NOT MCTD

MCTD requires the presence of specific clinical features beyond just anti-U1-RNP antibodies 2, 3:

• Missing scleroderma features: MCTD diagnosis strongly correlates with swollen hands, sclerodactyly, esophageal reflux, and Raynaud's phenomenon 2
• Absence of these features makes MCTD unlikely: The 2023 study specifically showed that patients meeting MCTD criteria were significantly more likely to display SSc features including sclerodactyly (p<0.01), swollen hands (p<0.01), and esophageal reflux (p<0.01) 2
• You haven't mentioned any of these: No Raynaud's, no hand swelling, no sclerodactyly, no esophageal symptoms

Why NOT SLE

SLE is less likely for several reasons:

• Isolated antibody profile: SLE typically presents with multiple positive antibodies (anti-dsDNA, anti-Sm, anti-Ro, anti-La) 4
• Your negative ENA panel argues strongly against SLE: When anti-U1-RNP patients also have SLE, they usually have additional autoantibodies 2
• Muscle weakness as primary presentation: While SLE-myositis overlap exists, it's rare (3.4-6.3% of SLE cases) and typically presents with other lupus features first 4
• No mention of other SLE criteria: No malar rash, photosensitivity, oral ulcers, serositis, renal involvement, or hematologic abnormalities

Critical Next Steps for Definitive Diagnosis

Immediate Workup Required 5

1. Muscle biopsy is essential:

   • Anti-U1-RNP myopathy shows necrotizing changes in 4 of 7 patients (57%) 1
   • This distinguishes it from dermatomyositis (perifascicular atrophy) and polymyositis (endomysial inflammation)
   • MRI-guided biopsy of proximal muscles showing edema on T2/STIR sequences 5

2. Complete myositis antibody panel:

   • Test for myositis-specific antibodies (anti-Jo-1, anti-Mi-2, anti-SRP, anti-HMGCR) 5, 6
   • These help define specific myopathy subtypes and predict organ involvement

3. Cardiac evaluation 5:

   • Troponin, ECG, echocardiogram
   • Anti-U1-RNP myositis can involve myocardium
   • Pericarditis occurs in 40% of anti-U1-RNP patients 1

4. Pulmonary screening 1:

   • High-resolution chest CT
   • Pulmonary function tests with DLCO
   • Interstitial lung disease occurs in 45% of anti-U1-RNP myopathy patients 1

5. Renal evaluation 1:

   • Urinalysis with microscopy
   • Urine protein-to-creatinine ratio
   • Glomerulonephritis occurs in 25% of anti-U1-RNP patients, but only in those with coexisting anti-Ro52 antibodies 1

Look for These Specific Features

Extramuscular manifestations that support anti-U1-RNP myopathy 1:

• Arthritis (60% prevalence—much higher than dermatomyositis at 18% or IMNM at 6%)
• DM-specific skin findings (60% develop Gottron's papules, heliotrope rash despite not having classic DM)
• Interstitial lung disease (45%)
• Pericarditis (40%—unique to anti-U1-RNP myopathy when compared to other inflammatory myopathies)

Prognosis and Key Distinctions

Favorable Prognostic Features 1

• No cancer association: Unlike dermatomyositis, anti-U1-RNP myopathy is NOT associated with malignancy
• No mortality in the study cohort: Zero deaths during follow-up period
• Younger age at onset: Better long-term outcomes

Critical Caveat About Anti-Ro52

If you test positive for anti-Ro52 antibodies in addition to anti-U1-RNP, your risk profile changes 1:

• Glomerulonephritis and pericarditis occurred exclusively in patients with both anti-U1-RNP AND anti-Ro52
• This subset may represent a more aggressive phenotype requiring closer monitoring

Treatment Approach

Based on inflammatory myopathy guidelines 5:

Initial therapy for moderate-to-severe weakness:

• High-dose corticosteroids (prednisone 1 mg/kg/day) 5
• Concurrent steroid-sparing agent from day one: methotrexate, azathioprine, or mycophenolate mofetil 5
• Do NOT wait to add steroid-sparing agents—start together to minimize cumulative steroid exposure

For severe or refractory disease 5:

• High-dose methylprednisolone IV
• IVIG therapy
• Consider rituximab, cyclophosphamide, or cyclosporine
• Plasmapheresis for life-threatening presentations

Common Pitfalls to Avoid

1. Don't assume MCTD just because anti-U1-RNP is positive: MCTD requires specific clinical features (especially scleroderma features) that you haven't described 2, 3

2. Don't delay muscle biopsy: Necrotizing changes on biopsy fundamentally alter treatment approach and prognosis 1

3. Don't miss cardiac involvement: Myocarditis can be asymptomatic but life-threatening 5

4. Don't forget pulmonary screening: ILD in anti-U1-RNP myopathy (45%) requires early detection and aggressive treatment 1

5. Don't overlook the need for anti-Ro52 testing: This modifies your risk for renal and cardiac complications 1